...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
【24h】

Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.

机译:接受骨髓移植的血液病患者的可溶性白介素6受体。

获取原文
获取原文并翻译 | 示例

摘要

Soluble interleukin-6 receptor (sIL-6R) has previously been shown to potentiate the activity of interleukin (IL)-6, which may display antitumor activity. We evaluated sIL-6R and IL-6 levels in the sera of 24 patients following transplantation (allogeneic, n=17; autologous, n=7). Five patients developed acute graft-versus-host disease (AGVHD), three had early graft rejection, and three had an early relapse following bone marrow transplantation (BMT). Soluble IL-6R levels were evaluated at day - 10, day 0, day of engraftment, and during BMT-related complications, using IL-6R-specific monoclonal antibodies (mAb) and double-sandwich ELISA. In normal controls, sIL-6R and IL-6 levels were 20+/-3 ng/ml and 0.01+/-0.005 ng/ml, respectively. Soluble IL-6R levels increased in direct correlation with engraftment in the uneventful allogeneic transplants (17.7+/-2.1 ng/ml at day 0 to 49.7+/-2.6 ng/ml at day of engraftment, n=6, P<0.05) as well as in the autologous transplants (26.8+/-2.82 at day 0 to 66.4+/-12.9 atday of engraftment, n=5, P=0.01). In contrast, IL-6 levels declined with time during the conditioning period and showed only a modest elevation following BMT. Increased levels of sIL-6R and IL-6 were found in the patients who developed AGVHD (23.8+/-4.2 and 0+/-0 ng/ml at day 0 to 79+/-6.9 and 0.26+/-0.04 ng/ml, respectively, at time of AGVHD, n=5, P=0.01). No correlation was found between the severity of AGVHD and sIL-6R levels. In the three patients with early relapse, sIL-6R levels increased from 30+/-0 ng/ml at day 0 to 90 ng/ml (P=0.05) and IL-6 levels increased from 0 to 0.16+/-0 ng/ml, respectively. The mean elevation of sIL-6R in the patients with early relapse and AGVHD was significantly higher than the mean elevation in the patients with the relatively smooth engraftment (P<0.05). Contrary to these findings, in the three patients with graft rejection, sIL-6R levels decreased while IL-6 was found to be elevated. Basic disease, conditioning regimen, type of transplant, GVHD propylaxis, and T cell depletion had no effect on sIL-6R or IL-6 levels. In summary, sIL-6R levels positively correlated with engraftment. Both sIL-6R and IL-6 levels were found to be significantly elevated in patients who developed AGVHD or early relapse following BMT. Therefore, the sIL-6R level may be used as a tool for assessing engraftment and transplant-related complications following BMT.
机译:先前已显示可溶性白介素6受体(sIL-6R)增强白介素(IL)-6的活性,而白介素(IL)-6可能具有抗肿瘤活性。我们评估了移植后24例患者血清中的sIL-6R和IL-6水平(同基因,n = 17;自体,n = 7)。五例患者发展为急性移植物抗宿主病(AGVHD),三例早期移植排斥反应,三例在骨髓移植(BMT)后早期复发。使用IL-6R特异性单克隆抗体(mAb)和双夹心ELISA在移植的第10天,第0天,移植当天和与BMT相关的并发症中评估可溶性IL-6R水平。在正常对照中,sIL-6R和IL-6水平分别为20 +/- 3 ng / ml和0.01 +/- 0.005 ng / ml。正常同种异体移植物中的可溶性IL-6R水平与移植直接相关(移植第0天为17.7 +/- 2.1 ng / ml,移植后第4天为49.7 +/- 2.6 ng / ml,n = 6,P <0.05)以及在自体移植中(植入后第0天为26.8 +/- 2.82,植入后第6天为66.4 +/- 12.9,n = 5,P = 0.01)。相反,IL-6水平在调理期间随时间下降,并且在BMT之后仅显示适度的升高。在第0天至79 +/- 6.9天和0.26 +/- 0.04 ng / ml患AGVHD的患者中发现sIL-6R和IL-6水平升高(23.8 +/- 4.2和0 +/- 0 ng / ml在AGVHD时分别为1ml,n = 5,P = 0.01。在AGVHD的严重程度与sIL-6R水平之间未发现相关性。在这三例早期复发的患者中,sIL-6R水平从第0天的30 +/- 0 ng / ml增加到90 ng / ml(P = 0.05),IL-6水平从0增加到0.16 +/- 0 ng / ml。早期复发和AGVHD患者中sIL-6R的平均升高显着高于移植相对顺利患者的sIL-6R的平均升高(P <0.05)。与这些发现相反,在三例移植排斥反应患者中,sIL-6R水平降低,而IL-6升高。基本疾病,调理方案,移植类型,GVHD丙基轴和T细胞耗竭对sIL-6R或IL-6水平无影响。综上所述,sIL-6R水平与移入呈正相关。发现AGVHD或BMT后早期复发的患者中sIL-6R和IL-6水平均显着升高。因此,sIL-6R水平可用作评估BMT后的植入和移植相关并发症的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号